The Parkinson Study Group: Clinical Trials

2 completed, 1 terminated. 3 Phase 3, 1 Phase 2.

By phase and status

Phase	Trials	Status
Phase 3	3	Completed 2, Terminated 1
Phase 2	1	Terminated 1

Follow The Parkinson Study Group: new trials by email

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Study of Urate Elevation in Parkinson's Disease, Phase 3 Inosine, Placebo - Parkinson's Disease	Phase 3	Completed	Michael Alan Schwarzschild	298	2016-06-01	2020-07-28
Efficacy of Isradipine in Early Parkinson Disease Isradipine, Placebo (for Isradipine) - Parkinson Disease	Phase 3	Completed	University of Rochester	336	2014-11-01	2020-01-14
Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease CEP-1347 10mg, CEP1347 25mg, CEP-1347 50mg - Parkinson Disease	Phase 2 / Phase 3	Terminated	Cephalon	806	2002-03-01	2012-05-10

Conditions studied

Parkinson Disease (3)

Interventions

3,9-bis((ethylthio)methyl)-K-252a (1)  ·  Inosine (1)  ·  Isradipine (1)

Countries

United States (3)  ·  Canada (2)  ·  Puerto Rico (2)

Top investigators

Alberto Ascherio, MD, DrPH (1)  ·  David Oakes, PhD (1)  ·  Eric A Macklin, PhD (1)  ·  Michael A Schwarzschild, MD, PhD (1)  ·  Robert Holloway, MD MPH (1)  ·  Tanya Simuni, MD (1)

Results publications

PMID 36865634, PMID 17881719, PMID 18413464, PMID 30741695, PMID 32227247, PMID 33460320, PMID 33942376, PMID 34519802

NIH funding

U01NS080818 (1), U01NS080840 (1), U01NS090259 (1)